JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Erosive Gastroesophageal Reflux Disease. Basic parameters: from 19 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Multi-center Prospective Observational Study to Evaluate the Effectiveness and Safety of JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive Gastroesophageal Reflux Disease
Overview
The purpose of this study is to evaluate the effectiveness and safety of JAQBO® Tab. 20 mg(Zastaprazan citrate) patients who have been prescribed the investigational drug.
Detailed description
Multi-center prospective observational study
Primary outcome measures
- Change in Reflux Disease Questionnaire (RDQ) at Week 8 [Time frame: Week 8]
Eligibility criteria
Inclusion criteria
- subjects aged 19 years or older who have been diagnosed with erosive reflux disease (ERD)
- subjects who have voluntarily decided to participate in this observational study and have provided written informed consent after receiving the study information and consent form
Exclusion criteria
- Subjects who fall under the contraindications listed in the precautions for use section of the approved labeling for Fexuclu tablets:
- Subjects with hypersensitivity or a history of hypersensitivity to the investigational drug or any of its components
- Subjects currently taking medications containing atazanavir, nelfinavir, or rilpivirine
- Pregnant women, women who may be pregnant, or breastfeeding women
- Subjects with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- Subjects deemed inappropriate for participation in the study at the investigator's discretion.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-crossover
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07115706 · JL-JAQ-403